GE Healthcare’s Next Generation Nuclear Cardiology Platform Goes Mainstream
Category: BioValleyDENVER, Co. - GE Healthcare announced it has received commitments from more than 100 customers globally for its innovative Alcyone technology, a nuclear cardiology platform combining cadmium zinc telluride detectors, focused pin-hole collimation, stationary data acquisition and 3D reconstruction, designed to help facilitate workflow efficiency and dose management while maintaining image quality.
“This revolution in GE Healthcare nuclear cardiology began in 2009 when we introduced our Alycone technology,” said Nathan Hermony, general manager of GE Healthcare’s Nuclear Imaging business. “Today, Alcyone technology has been adopted by clinicians around the world, a fact that we believe helps to validate its excellence in myocardial perfusion imaging and workflow. With our CZT-based technology strategy we are building a path to help clinicians maintain image quality while lowering dose and reducing exam time†, which could potentially have a positive impact on departments globally. GE Healthcare is continuously investing in CZT-based technology, as we believe CZT is helping revolutionize the industry and may potentially stimulate an era of growth in Nuclear Medicine.”
Alcyone technology is available on both the Discovery NM 530c and the Discovery NM/CT 570c. Alcyone’s significant improvement in sensitivity and zero equipment motion may enable the potential for new clinical applications for 3D dynamic acquisitions as well as the flexibility to manage patient dose more efficiently with up to four times lower injected dose. †
In February 2011, GE completed the acquisition of the assets of Orbotech Medical Solutions Ltd. (OMS), a subsidiary of Orbotech Ltd. (Orbotech), and a manufacturer of the CZT detectors used in the innovative Alcyone technology. Through the acquisition of OMS, GE Healthcare passed an important milestone in the growth of its Nuclear Medicine business.
Added Terri Bresenham, vice president and general manager of GE Healthcare’s Molecular Imaging business, “CZT based technology may help clinicians around the world provide patients with faster, and therefore potentially more comfortable, examinations at lower dose, and improve workflow while maintaining image quality†. We’ve entered a new frontier of possibilities in nuclear medicine as we employ CZT technology not only in cardiac exams, but apply it to other critical areas such the early detection of breast cancer.”
GE Healthcare’s Alcyone technology will be showcased with the Discovery NM 530c on display at the American Society of Nuclear Cardiology Annual Scientific Session in Denver, Colorado at booth 715.
† As compared to nuclear medicine gamma cameras using conventional detectors
About GE Healthcare:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.
Contacts:
Rebecca Hayne
GE Healthcare
414 721 3871